mHealth ALIBIRD: A Digital Health Care Model

Status Completed

Clinical Trial Summary

The aim of this pilot study was to evaluate the feasibility and acceptability of the ALIBIRD platform, a new mobile health (mHealth) application prototype design for personalized and remote support on the follow-up of cancer patients. The ALIBIRD platform is a mHealth intervention that tracks PROs, improving symptom control and allowing real-time feedback, and provides personalized recommendations and educational content, promoting empowerment and encourage healthy lifestyle behaviors in patients with thoracic neoplasms in active treatment.

Clinical Trial Description

The investigators have developed an innovative mHealth platform that provides personalized recommendations based on Patient Reported Outcomes (PROs) records and the study of patient´s nutrigenomics and gut microbiome. The usability of the ALIBIRD mHealth platform prototype is being tested in a 28-week pilot study carried out at Infanta Sofía Hospital. A small group of stage IV thoracic neoplasms patients (n=20) were asked to participate. All the participants gave informed consent. ;

Study Design

Related Conditions & MeSH terms

Thoracic Neoplasms

Clinical Trial Details

NCT number	NCT05770869
Study type	Interventional
Source	Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares
Contact
Status	Completed
Phase	N/A
Start date	November 5, 2021
Completion date	October 28, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06004440` - Real World Registry for Use of the Ion Endoluminal System
Completed	`NCT02909452` - Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT04741958` - Role of Ultrasound Guided Peripheral Thoracic Tumors	N/A
Recruiting	`NCT04556344` - Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer	N/A
Terminated	`NCT03306693` - Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers	N/A
Completed	`NCT04751552` - Erector Spinae Block for Thoracoscopic Surgery	N/A
Not yet recruiting	`NCT06104774` - The Effects of a Family-Centered Tai Chi Exercise on Lung Function and Mental Health of Patients After Thoracoscopic Surgery	N/A
Active, not recruiting	`NCT04589247` - Improving Cancer Symptom Management
Not yet recruiting	`NCT04133337` - Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC	Phase 1/Phase 2
Terminated	`NCT04644315` - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors	Phase 2
Completed	`NCT02188563` - A Comprehensive Smoking Cessation Intervention Duration Radiation for Upper Aerodigestive Cancers	N/A
Completed	`NCT03134872` - A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC	Phase 3
Not yet recruiting	`NCT04371796` - Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC	Phase 2
Completed	`NCT00437372` - Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients	Phase 1
Completed	`NCT03037385` - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT04862780` - (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	Phase 1/Phase 2
Recruiting	`NCT04776447` - Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)	Phase 2
Recruiting	`NCT05988736` - Comparison Between McGrath and Macintosh Laryngoscopes for DLT Intubation in Thoracic Surgery Patients.	N/A
Not yet recruiting	`NCT06376084` - Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
Active, not recruiting	`NCT04222972` - A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)	Phase 3